Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION) (ACTION)

5 de mayo de 2026 actualizado por: Faisal Sharif, University of Galway

Artificial Intelligence-assisted CT for Risk Stratification in COronary Artery Disease to PreveNt Future Coronary Events and Improve Outcomes

The goal of this observational study is to learn if AI-assisted cardiac CT imaging can improve cardiovascular risk stratification and prediction of future coronary events in an adult population undergoing clinically indicated cardiac CT.

The main questions it aims to answer are:

  • Can AI-enhanced cardiac CT accurately assess cardiovascular risk in a real-world adult population?
  • How do CT-derived plaque characteristics correlate with clinical, biochemical, and lifestyle risk factors? Researchers will compare subgroups (e.g., patients with different risk profiles, biomarkers, or imaging findings, and a subset undergoing OCT imaging) to see if differences in imaging and clinical parameters are associated with cardiovascular risk and plaque vulnerability.

Participants will:

  • Provide informed consent and medical history/demographic information
  • Undergo blood sampling for cardiovascular and metabolic biomarkers
  • Have a resting ECG performed
  • Complete a detailed lifestyle and health questionnaire
  • Receive a non-invasive cardiac CT scan interpreted by an expert
  • Potentially receive heart rate-lowering medication (e.g., metoprolol) if required for imaging quality
  • Be referred for further clinical evaluation if clinically indicated 

Descripción general del estudio

Descripción detallada

The ACTION Registry (Artificial Intelligence-assisted CT for Risk Stratification in Coronary Artery Disease) is a prospective, single-centre, observational patient registry conducted at the Clinical Research Facility, University Hospital Galway.

This registry is designed to systematically collect and integrate multimodal data from adults undergoing clinically indicated cardiac computed tomography (CT) to support advanced cardiovascular risk assessment using artificial intelligence (AI)-based approaches.

Registry Design and Procedures Eligible participants are consecutively enrolled at the time of referral for clinically indicated cardiac CT. Following informed consent, data are collected during a single baseline visit and supplemented by routine clinical data and follow-up information where available.

Registry procedures include:

  • Collection of demographic and clinical data from medical records
  • Blood sampling for cardiovascular and metabolic biomarkers
  • Resting electrocardiogram (ECG)
  • Structured questionnaires capturing lifestyle, cardiovascular history, and risk factors
  • Standard-of-care cardiac CT imaging acquisition and expert interpretation
  • Recording of medication use and clinically relevant interventions A subset of participants undergoing invasive imaging (e.g., optical coherence tomography) will have additional data collected for cross-modality comparison.

Data Collection and Registry Variables

The registry captures structured data across the following domains:

  • Clinical and demographic characteristics
  • Laboratory biomarkers
  • Imaging-derived parameters from cardiac CT
  • Lifestyle and behavioural factors
  • Treatment and medication data

All variables are defined in a standardized data dictionary, which specifies:

  • Variable definitions and formats
  • Source of data (e.g., imaging system, laboratory system, questionnaire)
  • Coding standards where applicable
  • Acceptable ranges and units Data Management and Quality Assurance All data are anonymised using unique participant identifiers and stored in secure, access-controlled electronic systems compliant with GDPR and institutional data governance policies.

A comprehensive quality assurance plan is implemented, including:

Data Validation and Entry Controls

  • Electronic data capture systems incorporate predefined validation rules
  • Range checks and logical consistency checks are applied at data entry
  • Automated queries are generated for missing, inconsistent, or out-of-range values Data Monitoring and Auditing
  • Periodic internal data reviews are conducted to ensure completeness and accuracy
  • Selected variables undergo source data verification against original records (e.g., imaging reports, laboratory systems, case report forms)
  • On-site or remote monitoring may be conducted in accordance with institutional policies Source Data Verification
  • A predefined proportion of records will be cross-checked with source documents
  • Discrepancies will be documented, reviewed, and resolved בהתאם standard procedures Standard Operating Procedures (SOPs)

Registry operations are governed by standardized procedures covering:

  • Participant recruitment and consent
  • Data collection and entry
  • Imaging acquisition and reporting
  • Laboratory data handling
  • Data management and security
  • Statistical analysis and reporting
  • Adverse event identification and reporting (if applicable)
  • Change management and protocol amendments Sample Size Considerations As an observational registry, the study aims to recruit a representative, real-world population of adults undergoing cardiac CT. The sample size is determined pragmatically based on recruitment feasibility and expected patient volume at the study site.

The anticipated sample size is sufficient to support:

  • Multivariable modelling for risk prediction
  • Subgroup analyses
  • Development and validation of AI-based models Handling of Missing Data

Missing or incomplete data may arise due to non-response, unavailable records, or technical limitations. The registry implements the following approach:

  • Real-time prompts to minimise missing data at entry
  • Documentation of reasons for missingness where available
  • Statistical handling using appropriate methods (e.g., multiple imputation, sensitivity analyses), depending on the extent and pattern of missing data Statistical Analysis Plan Analyses will be conducted in accordance with a predefined statistical analysis plan.

Approaches may include:

  • Descriptive statistics for baseline characteristics
  • Correlation analyses between imaging, clinical, and biomarker variables
  • Regression modelling for risk prediction and association analyses
  • Subgroup analyses across demographic and clinical strata
  • Cross-modality comparisons for imaging validation
  • Longitudinal analyses where follow-up data are available Model performance may be evaluated using appropriate metrics (e.g., discrimination, calibration, and reclassification measures).

Data Use and Future Applications

The registry is designed to support:

  • Clinical research and hypothesis generation
  • Development and validation of AI-based cardiovascular risk models
  • Integration of imaging and clinical data for precision medicine approaches An anonymised dataset will be maintained for future research, subject to governance and ethical approvals.

Ethical and Regulatory Considerations The registry is conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Ethical approval will be obtained from the appropriate research ethics committee, and all participants will provide written informed consent prior to inclusion

Tipo de estudio

De observación

Inscripción (Estimado)

10000

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Método de muestreo

Muestra no probabilística

Población de estudio

All-comers adult population undergoing clinically indicated cardiac CT in routine clinical care

Descripción

Inclusion Criteria:

  • Adults aged ≥18 years
  • Undergoing clinically indicated cardiac CT
  • Able and willing to provide informed consent

Exclusion Criteria:

  • History of malignancy
  • Abnormal renal function (e.g., eGFR or serum creatinine outside reference range)
  • Contraindications to iodinated contrast agents or CT imaging

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cardiovascular risk stratification using AI-assisted cardiac CT
Periodo de tiempo: Baseline
Assessment of cardiovascular risk based on AI-enhanced cardiac CT imaging, including coronary artery calcium scoring, plaque characterization, and integrated risk prediction using clinical and imaging data.
Baseline

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Correlation between CT-derived plaque characteristics and haematological biomarkers
Periodo de tiempo: Baseline
Association between imaging-derived plaque features and blood biomarkers (e.g., CRP, lipid profile, ApoB/ApoA-1 ratio).
Baseline
Concordance between coronary CT angiography (CCTA) and optical coherence tomography (OCT)
Periodo de tiempo: Baseline (subset undergoing OCT)
Agreement between CT-derived plaque characteristics and OCT findings in a subset of participants.
Baseline (subset undergoing OCT)
Association between lifestyle factors and imaging-derived plaque risk features
Periodo de tiempo: Baseline
ssociation between lifestyle factors (e.g., smoking, diet, occupation) and imaging-derived Parameters.
Baseline
Subgroup analyses of cardiovascular risk by demographic and clinical factors
Periodo de tiempo: Baseline
Differences in imaging and risk profiles across subgroups (age, sex, comorbidities, hormonal history).
Baseline
Longitudinal changes in plaque composition in patients receiving statin therapy
Periodo de tiempo: Baseline, 1 year, and annually up to 5 years
Evaluation of plaque progression or regression over time in participants on statin treatment.
Baseline, 1 year, and annually up to 5 years
Feasibility and utility of CT-derived fractional flow reserve (CT-FFR) and AI-based risk models
Periodo de tiempo: Baseline
Assessment of the applicability and performance of CT-FFR and AI-based models in risk prediction.
Baseline

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Development of an anonymized multimodal dataset for AI training and validation
Periodo de tiempo: through study completion, up to 10 years
Creation of a secure dataset integrating imaging, clinical, biomarker, and lifestyle data for future AI development.
through study completion, up to 10 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Faisal Sharif, MBBS, PhD, FRCPI, FESC, FACC, University of Galway

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

21 de diciembre de 2022

Finalización primaria (Estimado)

21 de diciembre de 2032

Finalización del estudio (Estimado)

21 de diciembre de 2032

Fechas de registro del estudio

Enviado por primera vez

28 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

5 de mayo de 2026

Publicado por primera vez (Actual)

11 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

11 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir